AtheroGenics (AGIX) Receives Delisting Notification From NASDAQ
More News related to AGIX
- AtheroGenics Seeks to Realign Capital Structure
- AtheroGenics Reports Second Quarter 2008 Financial Results
- BeaconEquity.com Issues Technical Trade Alerts on Market Movers: AGIX, APKT, BIOS, NOVA, CNXT, CHRD
- AtheroGenics Reports Positive Results From ANDES Phase 3 Clinical Trial of AGI-1067 in Type 2 Diabetes
- AtheroGenics to Report Second Quarter 2008 Financial Results on August 5, 2008
More News related to Corporate News
- Orthofix International (OFIX) Receives FDA 510(k) Approval
- Rosetta Genomics (ROSG) Identifies Potential microRNA Biomarkers in Blood Serum
- BioCryst Pharma (BCRX) Reports Results From BCX-4208 Phase IIa Trial in Subjects With Psoriasis
- Celgene (CELG) Granted FDA Fast Track Designation for Amrubicin
- GTC Biotherapeutics (GTCB) Granted Priority Review from the FDA
AtheroGenics, Inc. (NASDAQ: AGIX) received a Staff Determination Letter from the NASDAQ Listing Qualifications Department indicating that the Company has not regained compliance with the $1.00 per share bid price requirement for continued listing set forth in Marketplace Rule 4450(b)(4). As a result, shares of the Company's common stock are subject to delisting unless it requests a hearing before a NASDAQ Listing Qualifications Panel.
AtheroGenics plans to request a hearing before the Panel, at which it will request continued listing pending completion of its plan of compliance. The Company's request for a hearing will stay the delisting of the Company's common stock, and, as a result, shares of the Company's common stock will continue to be listed on The NASDAQ Global Market under the symbol AGIX until the Panel issues its decision following the hearing.
AtheroGenics, Inc. (AtheroGenics) is a research-based pharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
